- Home
- IMNN vs INAB Comparison
IMNN vs INAB Comparison
Compare IMNN & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- INAB
- Stock Information
- Founded
- IMNN 1982
- INAB 2016
- Country
- IMNN United States
- INAB United States
- Employees
- IMNN N/A
- INAB N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- IMNN Health Care
- INAB Health Care
- Exchange
- IMNN Nasdaq
- INAB Nasdaq
- Market Cap
- IMNN 12.1M
- INAB 14.5M
- IPO Year
- IMNN 1985
- INAB 2021
- Fundamental
- Price
- IMNN $7.61
- INAB $2.15
- Analyst Decision
- IMNN Buy
- INAB Strong Buy
- Analyst Count
- IMNN 2
- INAB 2
- Target Price
- IMNN $210.00
- INAB $108.00
- AVG Volume (30 Days)
- IMNN 405.2K
- INAB 151.7K
- Earning Date
- IMNN 08-05-2025
- INAB 08-07-2025
- Dividend Yield
- IMNN N/A
- INAB N/A
- EPS Growth
- IMNN N/A
- INAB N/A
- EPS
- IMNN N/A
- INAB N/A
- Revenue
- IMNN N/A
- INAB N/A
- Revenue This Year
- IMNN N/A
- INAB N/A
- Revenue Next Year
- IMNN N/A
- INAB N/A
- P/E Ratio
- IMNN N/A
- INAB N/A
- Revenue Growth
- IMNN N/A
- INAB N/A
- 52 Week Low
- IMNN $5.55
- INAB $2.05
- 52 Week High
- IMNN $54.75
- INAB $26.39
- Technical
- Relative Strength Index (RSI)
- IMNN 38.74
- INAB 38.59
- Support Level
- IMNN $6.51
- INAB $2.30
- Resistance Level
- IMNN $8.10
- INAB $2.57
- Average True Range (ATR)
- IMNN 1.32
- INAB 0.14
- MACD
- IMNN 0.20
- INAB 0.05
- Stochastic Oscillator
- IMNN 20.04
- INAB 6.67
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.